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Available online 23 January 2016AbstractIn leukemia, secondary infection is common and after chemotherapy the number of normal active neutrophil reduced significantly. Therefore,
to avoid side effects of chemotherapy and to induce neutrophil activity and number, in this study, we have treated with G-CSF plus IL-15 in
combination to NeN0 Ethylnitrosourea (ENU) induced leukemia in BALB/c mice. After 5 months of ENU treatment in 3e4 weeks old mice at
80 mg/kg body weight, leukemia was confirmed by histology of blood smear co-treatment started with cytokines for 5 days. The in vitro
phagocytosis activity of neutrophil from spleen was assayed using Dalton's lymphoma ascites as target cell. Using real time polymerase chain
reaction (RT-PCR), Toll like receptor 4 (TLR4) and toll like receptor 9 (TLR9) expression of neutrophil was also measured. Our data suggests
that G-CSF plus IL-15 induce the phagocytic activity of neutrophil. TLR4 and TLR9 expression was induced in neutrophil after treatment with
cytokines together which was significantly reduced in leukemia. In conclusion, G-CSF plus IL-15 has potential role as therapeutic immuno-
modulators for neutrophil activity in leukemia.
Copyright © 2016, Shanghai Hengrun Biomedical Technology Research Institute. Publishing services by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Leukemia is a type of cancer of the blood or bone marrow
characterized by an abnormal increase of immature white
blood cells. These immature cells accumulate in blood and
organs but all of them are not able to carry out the normal
functions of blood [1]. Due to increase the abnormal blood
cells in the peripheral blood the normal function of normal
immune cells are altered.
Specific doses of ENU, also known as N-ethyl-N-nitro-
sourea (chemical formula C3H7N3O2), can induce mixed type
of leukemia (both the myelogenous and lymphogenous) [2].
Neutrophils, the most abundant immune cell in blood quickly* Corresponding author.
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following infection. The key role of neutrophils is the anti-
microbial effector functions and the ability to produce cyto-
kines to initiate inflammatory responses and chemokines to
induce trafficking of immune cells [3].
During the beginning (acute) phase of inflammation, partic-
ularly as a result of bacterial infection, environmental exposure
[4], and some cancers [5], neutrophils are one of the first-
responders of inflammatory cells to migrate towards the site of
inflammation. In leukemia, the immune system is in depressed
condition and the infection by different microorganism in that
condition, is prevented generally by the neutrophils. In acute
leukemic condition the number of neutrophil decreased signifi-
cantly [6]. Neutrophils migrate through the blood vessels, then
through interstitial tissue, following chemical signals such as
Interleukin-8 (IL-8) and C5a by the process called chemotaxis
[7]. The neutrophils in chronic myeloid leukemia (CML) exhibit
defects in several functions [8].h Institute. Publishing services by Elsevier B.V. This is an open access article
.0/).
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between self and foreign pathogens through a process that
relies, to a great extent, on an evolutionary conserved family
of pattern recognition receptors, including TLRs. At least 13
TLRs have been identified in mammals to date and their li-
gands are predominantly pathogen-associated molecular pat-
terns, a limited set of conserved molecular patterns that are
unique to microbes [9]. TLRs are type 1 transmembrane
receptors that play important role in innate immune
recognition of pathogens [10]. Recognition of conserved mo-
lecular patterns found on microbes by these invariant, germ
line encoded receptors leads to a signal transduction cascade
that results in cellular activation and cytokine release in both
immune and non-immune cells.
Granulocyte colony stimulating factor (G-CSF) is a lineage
specific hematopoietic growth factor that initiates the differ-
entiation and proliferation of committed progenitor cells into
mature neutrophils. G-CSF exerts its proliferative effect
mainly at the stage of myeloblast-promyelocyte, and also
stimulates the release of mature bone marrow neutrophils from
storage pools into the peripheral circulation [11]. In vivo
studies of G-CSF administration reveals enhanced adhesion on
nylon wool, phagocytosis, luminal enhanced chem-
iluminescence, degranulation and expression of cell surface
antigens [12]. One study also showed promotion of neutrophil
survival in vitro [13]. After allogeneic stem cell transplantation
the patient with invasive fungal disease also improved with G-
CSF treatment [14].
IL-15 can induce phagocytosis, cytoskeleton rearrangement,
gene expression, de novo protein synthesis and can delay
apoptosis in human neutrophils [15]. Production of chemokines,
cytokines and natural inhibitors is increased in IL-15 induced
neutrophils, including CXCL8 (IL-8) [16], IL-1beta, IL-1RII and
IL-1Ra [17]. IL-15 has also been shown to induce the redistri-
bution of ICAM-3 and p-selectin glycoprotein ligand-1 (PSGL-
1) to the uropods in neutrophil [18]. The mechanisms involved in
IL-15-induced activation of human neutrophils are not fully
understood. However, IL-15 was shown to activate NFk-b [19],
and to induce the phosphorylation of Syk and its physical asso-
ciation with IL15R-a [20].
As the combined treatment approach with IL-15 and G-
CSF to leukemia animal has not been well studied to evaluate
their immunological response, our focus of this study was to
evaluate the neutrophil immunological activity such as
phagocytic activity during pre and post treatment with com-
binations of cytokines in ENU induced leukemia model. The
molecular changes like the expression of pattern recognition
molecules like TLR4, TLR9 and alteration of PTK activity in
both the conditions were evaluated.
2. Materials and methods2.1. MaterialsNitroblue tetrazolium (NBT) Hydrocloric acid (HCL), and
Pyridine were purchased from SRL chemicals, India. Lipo-
polysaccharide (LPS), and N-ethyl-N0-nitrosourea (ENU) werepurchased from Sigma Aldrich, USA. Leishman's stain was
purchased from Loba chemicals, India.
Dalton's lymphoma ascites are the kind gift from Dr.
Nabyendu Murmu, CNCI, Kolkata India. RPMI-1640, Fetal
Bovine Serum was purchased from Hi-media, India. Recom-
binant mouse interleukin-15 (rmIL-15), recombinant mouse
granulocyte colony stimulating factor (rmG-CSF) were pur-
chased from ImmunoTools, Germany. Percol was purchased
from GE Health Care Life Sciences, Uplasa, Sweeden. Pure-
ZOL™ RNA isolation reagent, iTaq™ universal SYBR®
Green Supermix, kit, iScript™ c-DNA synthesis kit were
purchased from BioRad, USA.2.2. AnimalsHealthy BALB/c male mice were obtained from National
Centre for Laboratory Animal Sciences, (NCLAS), NIN,
Hyderabad, India. Animals were divided into four groups
having six animals in each group. Groups were divided as
Mock control, ENU challenged, and control along with com-
bination cytokine treatment and ENU along with combination
cytokine treatment. These mice were kept and maintained
specific pathogen free condition in Tripura University Animal
House as per guidelines of Institutional Animal Ethical
Committee. Food, dietary supplements and water were pro-
vided ad libitum.2.3. Induction of leukemiaWe have induced leukemia previously in our lab
following the reference of Law et al., 2003 and detailed
protocol has been published [21]. In short leukemia was
induced by injecting N-ethyl-N0-nitrosourea (ENU) intra-
peritoneally (i.p.) to 7e10 days old mice, at the dose of
80 mg/kg body weight concentration at two times in one
week interval. The peripheral blood and bone marrow slides
were prepared for both control and treated group and stained
with Leishman's stain. Total count and differential count of
leukocytes were also done in all the four groups to confirm
leukemia [21].2.4. Cytokine treatmentENU treated groups were followed up for leukemia in-
duction after 4 months in one week interval. After 5 months of
ENU injection leukemia was confirmed by peripheral blood
smear observation. The two cytokines, rmG-CSF at the dose
rate of 10 mg/kg body weight [22] and rmIL-15 at the dose of
5 mg/kg body weight [23] were injected (i.p.) in animals of one
control and one ENU treated group after confirmation of
leukemic induction for consecutive five days.2.5. Isolation of splenic neutrophilsNeutrophils were isolated from the spleen as previously
described [21]. In short, the splenic suspension was made by
smashing the spleen gently by two frosted glass slides in a
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10% FBS after collecting the spleens from sacrificed mice.
Two layered Percol™ gradient was used to isolate neutrophils
[24]. Cell suspension was layered on 1.11 gm/ml density and
1.089 gm/ml density percol and centrifuged at 900 g for
30 min at room temperature. The interphase between two
layers consisting neutrophils were washed in phosphate
buffer saline (PBS) and finally suspended in complete RPMI-
1640 media. Total number of cells were counted by
haemocytometer.2.6. Phagocytic activity assay for neutrophilsDalton's lymphoma ascites were used as target cells. Neu-
trophils were sized at 3e4  106/ml. Daltons lymphoma cells
are collected and sized into 3e4  105/ml respectively and
mixed effector: target ¼ 10:1 (4  106: 4  105) in the
presence of 1% NBT in normal saline (200 ml)/sample and
15 ml of LPS (Stock: 10 mg/ml) and incubated at 37 C for
overnight (18 h) at 5% CO2 air environment [25]. The reaction
was stopped by adding by 0.1 N HCl (chilled) (2 ml). The cells
were pelleted by centrifugation and supernatant discarded. The
pellet was resuspended by adding 3 ml of pyridine in each tube
and boiled for 15 min in boiling water bath. Tubes were cooled
and centrifuged and the supernatant taken to read at 530 nm
wavelength. Experiment was repeated thrice and results
expressed as mean ± SD.
Percent phagocytosis was calculated as:
%phagocytosis¼ OpticaldensityðO:D:Þof test
O:D:of controlO:D:spontaneouslysis1002.7. Real time polymerase chain reaction (RT-PCR)Total RNA was isolated from the neutrophils using
PureZOL™ RNA isolation reagent, according to the manu-
facturer's protocol. In brief, isolated neutrophils of each
group 2.5e4.5  107 cells were used for isolation in tripli-
cate. Cells were pelleted down by centrifuging at
3000e5000 g for 5 min and supernatant containing media
was discarded. 1 ml PureZOL reagent was added in each
tube and incubated at room temperature for 5 min 0.2 ml of
chloroform for each 1 ml of PureZOL was added in each
tube and incubated for 5 min at room temperature. The tubes
were centrifuged at 12,000 g for 15 min at 4 C. The whole
mixture was separated into three phases, an upper colorless
aqueous phase, a white interphase and a lower organic phase.
The upper aqueous phase was collected carefully in a new
1.5 ml sterile tube and 0.5 ml of isopropyl alcohol was added
in each tube, mixed well and incubated for 5 min at room
temperature. Mixtures were centrifuged at 12,000 g for
10 min at 4 C. The RNA was precipitated as white pellet on
the bottom of the tube and the supernatant was discarded.
The RNA pellet was washed with 1 ml of 75% ethanol twice
and air dried. The RNA was reconstituted in nuclease freeDEPC-treated water and quantitated using synergy H1-hibrid
plate reader.
The complementary DNA was synthesized from isolated
RNAwas done using iScript™ c-DNA synthesis kit, according
to the manufacturer's protocol. 1 mg of RNA was used in c-
DNA synthesis for each group in triplicate. In brief, 20 ml of
reaction mixture components were, 4 ml of 5 iScript™ re-
action mix, 1 ml of iScript™ reverse transcriptase, 1 ml of RNA
solution and 14 ml of nuclease free water. Reaction protocol:
5 min at 25 C, 30 min at 42 C, 5 min at 85 C. After
completion of the samples were stored at 80 C for future
downstream RT-PCR experiments.
Real time polymerase chain reaction (RT-PCR) was done to
evaluate the expression of Toll like receptor 4 (TLR4, forward
50-CTGGCTGGTTTACACGTCCA-30: reverse 50-GCTGCA
GCTCTTCTAGACCC-30) and toll like receptor 9 (TLR9,
Forward 50-GCCTGAGCCACACCAACATCCT-30 reverse 50-
CCAGACCTTGGAACCAGGAAGA-30) gene along with
endogenous control glyceraldehyde 3 phosphate dehydroge-
nase (GAPDH, forward 50 CACCACCCTGTTGCTGTAGCC-
30: reverse 5-ACCACAGTCCATGCCATCAC-30) using
iTaq™ universal SYBR® Green Supermix, kit, according to
the manufacturer's protocol in Step One Plus 96 well real time
PCR system, Applied Biosystems, USA. Total reaction
mixture of 10 ml of was prepared using 5 ml of iTaq™ uni-
versal SYBR® Green Supermix (2), 1 ml forward and reverse
primer (10 mM concentration each) of gene of interest, 1 ml of
c-DNA template (1 mg) and 2 ml of nuclease free water. A
negative control was run along with each set of primers to
eliminate unwanted exogenous amplification like primer dimer
and contamination. To discriminate specific amplification
from nonspecific amplification, melting curve analysis was
performed at the end of each PCR assay. To determine the
starting c-DNA amount, purified PCR products with known
concentrations were serially diluted. PCR conditions used for
all the primer sets were as follows: 95 C hot start for 5 min,
followed by 40 amplification cycles of 95 C for 20 s (dena-
turing), 59Ce55 C (annealing temp, according to the Tm
values of the set of primers), 72 C for 30 s (extension). A melt
curve analysis was also done using instruments default settings
to detect any exogenous contamination with negative controls
for each set primers. GAPDH was used as endogenous control.
Expression of gene of interest was calculated using the Ct
values of the corresponding genes in reference with the
endogenous control, GAPDH. All the experiments were done
5 times. The RT-PCR products with equal volume were further
run through agarose gel for all the three genes to observe the
band pattern with a 100 bp ladder. Experiment was repeated 5
times and results expressed as mean ± SD.
3. Statistical analysis
All the readings were taken 3e5 times repeat of the same
experiment and expressed as mean ± SD using MS excel 2010
software. Data were analysed by student's t-test using Graph-
Pad Prism online software.
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leukemiaSecondary infection is common in leukemia patient. The
active neutrophil may help to protect this infection and in this
study we studied the activity of neutrophil in ENU induced
leukemic BALB/c mice. The neutrophils were isolated from
spleen of ENU induced leukemic mice [23] and used to assay
the in vitro phagocytic activity against Dalton's lymphoma
ascites cells as target. We have shown earlier that the number
of neutrophil decreased in leukemia [20] and in this study, the
phagocytic activity of the neutrophil was evaluated. This ac-
tivity was significantly reduced in leukemia which is reinstated
upon co-treatment with IL-15 plus G-CSF (Fig. 1).4.2. Neutrophil activity was regulated through TLR4 and
TLR9 expression in leukemiaDuring tumour development, immune suppression is one of
the major cause of secondary infection and growth of tumour
cells. The phagocytic activity of neutrophils depends on
expression of TLR4 and TLR9 [26]. More the expression of
these proteins in neutrophil better will be the recognition of
pathogen or tumor cell. Both pro-tumor and anti-tumor effect
of neutrophil has been reported [27].
The expression of TLR4 (Fig. 2A and B) and TLR9
(Fig. 3A and B) was significantly reduced in ENU induced
leukemic group of animals in compared to the control group.
But co-treatment with IL-15 and G-CSF, both TLR4 and
TLR9 expression increased significantly which also increased
the phagocytic activity of neutrophil.
5. Discussion
ENU is being used as a potent carcinogenic agent [28,29]
which can induce several cancer including brain tumourFig. 1. Phagocytic assay. Bar diagram showing % phagocytic activity of
neutrophil in different groups of animal. In leukemia, the functional activity
was reduced around 3.5 times compared to control. ( p¼ < 0.0001 between
control and ENU, p¼ < 0.0001 between ENU and ENU þ G-CSF þ IL-15)
This activity was regained in leukemic animal after co-treatment with G-CSF
and IL-15 in combination. (p < 0.05 indicates *, p < 0.01 indicates **,
p < 0.001indicates ***).[30], reproductive tumour [31], leukemia etc. in animal model.
In this present study, BALB/c mice were used to induce leu-
kemia by injecting ENU [32,33]. ENU, a carcinogen, can
cause immune suppression in animal [34,35] and so the tumor
load increased gradually in animal. To combat against tumor
cells the manipulation is required to increase the number of
normal immune cells in peripheral blood. G-CSF is a growth
factor to proliferate and differentiate granulocyte cells. It is
also reported that G-CSF can induce the expression of TLR9
to recognize pathogen [36]. IL-15 has also important role in
innate immune response.
One of the major immunological responses of neutrophils is
the phagocytic activity. Neutrophil has tumoricidal activity
besides the phagocytosis to pathogen [26]. TGF-b inhibition
causes the tumoricidal activity of the neutrophil [37]. By
increasing the production of TNF-a, MIP1a, H2O2 and NO,
neutrophil can kill the tumor cells in absence of TGF-b.
Through tumor antibody dependent cell mediated cytotoxicity
neutrophil can kill tumor cells though there are lacks of evi-
dences for this activity.
Our results showed that the phagocytic activity of neu-
trophils was down regulated in ENU induced leukemic mice
probably due to inhibitory character of carcinogen and/or the
lack of recognition of the tumor cells. This recognition is
dependent on the expression of TLRs. In this study both
TLR4 and TLR9 expression was significantly reduced in
leukemic mice. In this study, in vitro phagocytosis activity
was significantly reduced in the leukemia group. Also
reduced number of neutrophils in ENU group interferes with
the functional activity. But after the co-treatment with G-CSF
and IL-15 in combination, phagocytic activity restored even
more than control levels. Inducing tumor cells to release G-
CSF, enhance the neutrophil population towards the tumor
site and can regress the tumor load in vivo [38]. Interleukin-
15 plays a very crucial role in phagocytic activity of neu-
trophils by recruiting dendritic cells and generating cytotoxic
T lymphocytes against cancer cells [39]. Along with that, the
ability of G-CSF to consistently induce white blood cell
counts confirms its role as a potent hematopoietic growth
factor, particularly for cells of the granulocytic lineage [40].
Recent studies have suggested that human and mouse neu-
trophils used to kill target cells using TLRs, specially TLR4
and TLR9 as a mechanism of suppression and used in recent
therapeutic approach [41].
In this study, the expression of both TLR4 and TLR9 has
reduced in leukemic condition, and after co-treatment with G-
CSF and IL-15, the expression level was almost equal to the
control group. Altogether, co-treatment with G-CSF and IL-15
increases the phagocytic activity of neutrophil in leukemic
animal, may be through their TLR4 and TLR9 expression
pathway.
6. Conclusion
In tumor, immune suppression is common and neutrophil
can participate in tumor killing. Treatment with G-CSF and
IL-15 in combination induced the phagocytic activity of
Fig. 2. Expression of TLR4 in neutrophil. A. Bar diagram showing relative mRNA expression of TLR4 in neutrophils isolated from spleen of different groups of
animals. ( p ¼ 0.0085 between control and ENU, p ¼ 0.0005 between ENU and ENU þ G-CSF þ IL-15) B. RT-PCR products were loaded taking same volume in
agarose gel. (p < 0.05 indicates *, p < 0.01 indicates **, p < 0.001indicates ***).
Fig. 3. Expression of TLR9 in neutrophil. A. Bar diagram showing relative mRNA expression of TLR9 in neutrophils isolated from spleen of different groups of
animals. p ¼ 0.0002 between control and ENU, p ¼ 0.0002 between ENU and ENU þ G-CSF þ IL-15 B. RT-PCR products were loaded taking equal volume in
agarose gel. (p < 0.05 indicates *, p < 0.01 indicates **, p < 0.001indicates ***).
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the TLR4 and TLR9 expression on neutrophil in BALB/c
leukemia model.
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